Immunomodulatory lipopeptides are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, ophtalmology and respiratory care, as standalone drugs or as part of steroid-sparing therapeutic approaches.
EVO Lipopeptides
EVORA Biosciences develops EVO lipopeptides. Novel, patent-protected lipopeptides which exhibit strong anti-inflammatory potency alongside a very favorable profile for development as steroid-sparing drugs.
- Selective anti-inflammatory effect
- Stable
- Non-toxic
- Amenable to multiple formulation options
Management
Hadrien Lanvin, MSc
CEO
CEO
Anna Kostrzak, PhD
Head of R&D
Head of R&D
Directors
Hadrien Lanvin, MSc
CEO EVORA
CEO EVORA
Bruno Toque, PhD
Ex-Founder, CEO Exonhit Therapeutics
Ex-Founder, CEO Exonhit Therapeutics
Philippe Rousseau, MSc
CEO Xenothera
CEO Xenothera
Rémi Gloeckler, PhD
Ex-VP Industrial Partnerships, Ex-VP Industrial Operations
Transgene
Ex-VP Industrial Partnerships, Ex-VP Industrial Operations
Transgene
Partners Network
EVORA Biosciences is supported by
contact@evorabio.com
© EVORA Biosciences 2024